Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome.
OBJECTIVE
In order to better understand provider treatment patterns for interstitial cystitis (IC)/painful bladder syndrome, we sought to document the therapies utilized and their associated expenditures using a national dataset.


METHODS
A cohort was created by applying the ICD-9 diagnosis of IC (595.1) to INGENIX claims for the year 1999. Subjects were followed for 5 years, and patterns of care and related expenditures were evaluated.


RESULTS
Of 553,910 adults insured in 1999, 89 subjects had a diagnosis of IC with 5-year follow-up data. All subjects were treated with oral medication(s), 26% received intravesical treatments, and 22% underwent hydrodistension. Total expenditures per subject were $2,808.


CONCLUSIONS
The majority of IC expenditures were attributable to oral medical therapy. Hydrodistension and intravesical instillations were utilized in less than 25% of patients. Hydrodistension was used more frequently among subjects with a new diagnosis; this may reflect its utilization as part of a diagnostic algorithm.
Anger
Jennifer T
JT
Department of Urology, UCLA, Box 951738, Los Angeles, CA 90095-1738, USA.
Zabihi
Nasim
N
Clemens
J Quentin
JQ
Payne
Christopher K
CK
Saigal
Christopher S
CS
Rodriguez
Larissa V
LV
D000283:Administration, Intravesical; D000284:Administration, Oral; D018759:Adrenergic Uptake Inhibitors / Q000191:economics / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000588:Amines / Q000191:economics / Q000627:therapeutic use; D000639:Amitriptyline / Q000191:economics / Q000627:therapeutic use; D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000191:economics / Q000627:therapeutic use; D018856:Cystitis, Interstitial / Q000188:drug therapy* / Q000191:economics; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000191:economics / Q000627:therapeutic use*; D009294:Narcotics / Q000191:economics / Q000627:therapeutic use*; D010426:Pentosan Sulfuric Polyester / Q000191:economics / Q000627:therapeutic use; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome; D055815:Young Adult; D005680:gamma-Aminobutyric Acid / Q000191:economics / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000588:Amines; D000925:Anticoagulants; D003509:Cyclohexanecarboxylic Acids; D018727:Muscarinic Antagonists; D009294:Narcotics; D000639:Amitriptyline; D010426:Pentosan Sulfuric Polyester; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
Urology. 2000 Dec 20;56(6):940-5
11113737
Arch Intern Med. 2007 Oct 8;167(18):1922-9
17923590
J Urol. 2000 Aug;164(2):423-7
10893601
Urology. 2005 Nov;66(5):935-40
16286098
Ann Chir Gynaecol Fenn. 1975;64(2):75-7
1137336
Urology. 1997 May;49(5A Suppl):64-75
9146004
Clin Obstet Gynecol. 2003 Dec;46(4):797-803
14595221
J Urol. 1999 Feb;161(2):553-7
9915447
J Urol. 2005 Nov;174(5):1837-40
16217303
Urology. 2005 Sep;66(3):494-9
16140064
Drug Saf. 2005;28(7):583-600
15963006
J Urol. 2007 Jun;177(6):2042-9
17509284
J Urol. 2004 Aug;172(2):533-6
15247722
South Med J. 2000 Feb;93(2):238-42
10701800
Int Braz J Urol. 2006 Sep-Oct;32(5):513-20
17081319
Urology. 2008 May;71(5):776-80; discussion 780-1
18329077
J Urol. 2003 Sep;170(3):810-5
12913705
Med Clin North Am. 2004 Mar;88(2):467-81, xii
15049588
J Urol. 2005 Aug;174(2):576-80
16006901
Urology. 1997 May;49(5A Suppl):2-9
9145997